REG - ValiRx PLC - Result of AGM <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

20/06/2016 14:25

RNS Number : 7198B
ValiRx PLC
20 June 2016
ValiRx Plc
("ValiRx"or "theCompany")
RESULT OF ANNUAL GENERAL MEETING 
London, UK, 20th June 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, announces that at its Annual General Meeting ("AGM") held earlier today, Resolutions 1 to 5 were passed. Resolution 6, whilst supported by the majority of Shareholders, did not receive the necessary level of support to be passed at this time. A further announcement will follow in due course.
*** ENDS ***
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive
Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.
Tel: +44 (0) 7879 458 364
tarquin.edwards@valirx.com
Mark Treharne, Corporate Development Manager
Tel: +44 (0) 7736 564 686
mark.treharne@valirx.com


Cairn Financial Advisers LLP (Nominated Adviser)
Tel: +44 (0) 20 7148 7900
Liam Murray



Northland Capital Partners Limited (Joint Broker)
Tel: +44 (0) 203 861 6625
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Abigail Wayne (Broking)



Beaufort Securities Limited (Joint Broker)
Tel: +44 (0) 207 382 8300
Jon Belliss


This information is provided by RNS
The company news service from the London Stock Exchange
  END
RAGSEEFDSFMSEEM